Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing panel-based tumor mutational burden (TMB) measurement.
Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Budczies J, et al. Among authors: thomas m. Ann Oncol. 2019 Sep 1;30(9):1496-1506. doi: 10.1093/annonc/mdz205. Ann Oncol. 2019. PMID: 31268125 Free article.
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: thomas m. Lung Cancer. 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007. Epub 2020 Aug 22. Lung Cancer. 2020. PMID: 32871455
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgäuer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Fröhling S, Schirmacher P, Thomas M, Budczies J, Christopoulos P, Stenzinger A. Kirchner M, et al. Among authors: thomas m. ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3. ESMO Open. 2021. PMID: 34487971 Free PMC article.
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.
El Shafie RA, Seidensaal K, Bozorgmehr F, Kazdal D, Eichkorn T, Elshiaty M, Weber D, Allgäuer M, König L, Lang K, Forster T, Arians N, Rieken S, Heussel CP, Herth FJ, Thomas M, Stenzinger A, Debus J, Christopoulos P. El Shafie RA, et al. Among authors: thomas m. ESMO Open. 2021 Jun;6(3):100161. doi: 10.1016/j.esmoop.2021.100161. Epub 2021 Jun 2. ESMO Open. 2021. PMID: 34090172 Free PMC article.
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel PA, Serke M, Thomas M. Christopoulos P, et al. Among authors: thomas m. Ann Oncol. 2017 Aug 1;28(8):1898-1902. doi: 10.1093/annonc/mdx268. Ann Oncol. 2017. PMID: 28535181 Free article. Clinical Trial.
Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.
Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, Goeppert B, Thomas M, Herth FJ, Schirmacher P, Schnabel PA, Hoffmann H, Dienemann H, Muley T, Weichert W. Warth A, et al. Among authors: thomas m. Br J Cancer. 2014 Sep 9;111(6):1222-9. doi: 10.1038/bjc.2014.402. Epub 2014 Jul 22. Br J Cancer. 2014. PMID: 25051406 Free PMC article.
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Mountzios G, et al. Among authors: thomas m. ESMO Open. 2021 Oct;6(5):100254. doi: 10.1016/j.esmoop.2021.100254. Epub 2021 Sep 1. ESMO Open. 2021. PMID: 34481329 Free PMC article.
[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].
Schuette W, Eberhardt WE, Waller C, Schirmacher P, Dietel M, Zirrgiebel U, Radke S, Thomas M. Schuette W, et al. Among authors: thomas m. Pneumologie. 2016 Sep;70(9):579-88. doi: 10.1055/s-0042-109760. Epub 2016 Sep 7. Pneumologie. 2016. PMID: 27603946 Free article. Clinical Trial. German.
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber RM, Wolf M; IMPULSE study team. Thomas M, et al. Ann Oncol. 2018 Oct 1;29(10):2076-2084. doi: 10.1093/annonc/mdy326. Ann Oncol. 2018. PMID: 30137193 Free PMC article. Clinical Trial.
11,060 results
You have reached the last available page of results. Please see the User Guide for more information.